Bethesda proposals for classification of lymphoid neoplasms in mice

被引:249
作者
Morse, HC
Anver, MR
Fredrickson, TN
Haines, DC
Harris, AW
Harris, NL
Jaffe, ES
Kogan, SC
MacLennan, ICM
Pattengale, PK
Ward, JM
机构
[1] NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA
[2] NCI, Hematopathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA
[3] NCI, Pathol Histotechnol Lab, SAIC Frederick, NIH, Frederick, MD 21701 USA
[4] NCI, Vet & Tumor Pathl Sect, Ctr Canc Res, NIH, Frederick, MD 21701 USA
[5] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia
[6] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[7] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
[8] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[9] Univ Birmingham, Sch Med, Birmingham, W Midlands, England
关键词
D O I
10.1182/blood.V100.1.246
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A consensus system for classification of mouse lymphoid neoplasms according to their histopathologic and genetic features has been an elusive target for investigators involved in understanding the pathogenesis of spontaneous cancers or modeling human hematopoietic diseases in mice. An international panel of scientists with expertise in mouse and human hematopathology joined with the hematopathology subcommittee of the Mouse Models for Human Cancers Consortium to develop criteria for definition and classification of these diseases together with a standardized nomenclature. The fundamental elements contributing to the scheme are clinical features, morphology, immunophenotype, and genetic characteristics. The resulting classification has numerous parallels to the World Health Organization classification of human lymphoid tumors while recognizing differences that may be species specific. The classification should facilitate communications about mouse models of human lymphoid diseases.
引用
收藏
页码:246 / 258
页数:13
相关论文
共 47 条
[1]  
[Anonymous], 1981, HISTOPATHOLOGY NONHO
[2]  
[Anonymous], 1966, C SECT 3 FASE
[3]   Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway [J].
Baldassarre, G ;
Fedele, M ;
Battista, S ;
Vecchione, A ;
Klein-Szanto, AJP ;
Santoro, M ;
Waldmann, TA ;
Azimi, N ;
Croce, CM ;
Fusco, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (14) :7970-7975
[4]  
DAVIDSON WF, 1986, J IMMUNOL, V136, P4075
[5]   Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions [J].
Davidson, WF ;
Giese, T ;
Fredrickson, TN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1825-1838
[6]  
DUNN TB, 1954, JNCI-J NATL CANCER I, V14, P1281
[7]  
ENNO A, 1995, AM J PATHOL, V147, P217
[8]   Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells [J].
Fehniger, TA ;
Suzuki, K ;
Ponnappan, A ;
VanDeusen, JB ;
Cooper, MA ;
Florea, SM ;
Freud, AG ;
Robinson, ML ;
Durbin, J ;
Caligiuri, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (02) :219-231
[9]  
Fredrickson T N, 1995, Curr Top Microbiol Immunol, V194, P109
[10]   Splenic marginal zone lymphomas of mice [J].
Fredrickson, TN ;
Lennert, K ;
Chattopadhyay, SK ;
Morse, HC ;
Hartley, JW .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (03) :805-812